Skip to content
Hemispherx Biopharma, Inc. Logo
  • COMPANY
  • PRODUCTS
  • R & D
    • Product Candidates Overview
    • Pipeline
    • Orphan Drug Designations
  • PARTNERING
  • INVESTOR RELATIONS
    • Press Releases
    • Events & Presentations
    • Stock Information
    • SEC Filings
    • XBRL Filings
    • Stockholder Meeting
    • Corporate Governance
    • Email Alerts
    • Investor Contact
  • BLOG
  • CONTACT

Press Releases

 
Apr 30, 2004
Hemispherx Biopharma Accelerates Release Date on Phase 3 Data for Ampligen in CFS

Apr 20, 2004
HEMISPHERX BIOPHARMA CEO TO PRESENT AT WHITE MOUNTAIN CAPITAL BIOTECHNOLOGY CONFERENCE

Apr 19, 2004
HEMISPHERX BIOPHARMA REPORTS PUBLICATION SHOWING SUPERIOR ACTIVITY OF ALFERON AGAINST SARS

Apr 13, 2004
Hemispherx Biopharma to Present First Phase 3 Data on Ampligen in Chronic Fatigue Syndrome at the 17th International Conference on Antiviral Research

Mar 18, 2004
Hemispherx Biopharma Completes Acquisition for Worldwide Rights to Alferon N

Mar 15, 2004
HEMISPHERX BIOPHARMA REPORTS 2003 YEAR-END RESULTS

Mar 02, 2004
HEMISPHERX BIOPHARMA ANNOUNCES FDA AUTHORIZATION FOR A CLINICAL STUDY WITH NEW BIOLOGICAL ALFERON LDO FOR HIV

Feb 25, 2004
HEMISPHERX BIOPHARMA TO PRESENT AT WALL STREET ANALYST FORUM ON MARCH 1st

Feb 18, 2004
HEMISPHERX BIOPHARMA SIGNS OPTION AGREEMENT FOR AMPLIGEN WITH FUJISAWA PHARMACEUTICAL COMPANY

Jan 30, 2004
HEMISPHERX BIOPHARMA FINISHES PHASE 3 CFS CLINICAL TRIAL

 60   61   62   63   64     65    66   67   68   69   70 
 <<   <   >   >> 
Hemispherx Biopharma, Inc. Logo White

Latest News

  • CEO Roadshow Interviews Hemispherx Thomas K. Equels
  • Introducing You to the First Ampligen Quarterly Update
  • Proactive Investors USA Sits Down with Hemispherx CEO Thomas K. Equels

Privacy / Terms of Use

  • Terms Of Use
  • Investor Contact

Tweets by AIM Immuno

© Copyright | All Rights Reserved | AIM ImmunoTech Inc. | Privacy Policy | Terms of Use
FacebookTwitterYouTubeLinkedIn

Privacy
Resize Viewer - Reduce Resize Viewer - Expand Close window